A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
RougeTx
Preclinical biotech developing oral therapies that restore blood vessel stability by targeting pericyte dysfunction.
What they do
RougeTx launched in October 2026 with a $58M Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners with the EIB Aurea facility. Its lead program RTX-001, a once-daily oral small molecule, is advancing toward first-in-human studies in hereditary hemorrhagic telangiectasia, and its periSCOPE platform supports a wider vascular pipeline.
The record
- Vertical
- Biotech & Therapeutics
- Sub-segment
- Vascular and rare disease
- Product type
- Therapeutic
- Stage
- Series A
- Headquarters
- Naarden, Netherlands
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- $58M raised
Notable investors: BioGeneration Ventures, Angelini Ventures, Kurma Partners, EIB Aurea, Epidarex Capital, Vesalius Biocapital Partners.
Also in Biotech & Therapeutics
Related on The Signal
Dr. Dereck Mush, MD, MBA
Upfront Disease Modification: How Winrevair's HYPERION Label Update Rewrites Pulmonary Vascular Care
Dr. Dereck Mush, MD, MBA
Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBA
The ALK2 Opening: What Atebrioz Means for Rare Bone Disease
Dr. Dereck Mush, MD, MBA